The Susanne-Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel.
Breast Cancer Res Treat. 2012 Feb;131(3):981-5. doi: 10.1007/s10549-011-1807-5. Epub 2011 Oct 9.
Previous studies suggested that appendectomy may affect cancer risk in the general population. No data on the effect of appendectomy on cancer risk in BRCA1 and BRCA2 carriers is available. Data on appendectomy, cancer type, and age at diagnosis were collected from BRCA1 (n = 677) and BRCA2 (n = 270) female Jewish Israeli mutation carriers counseled in a single medical center. Data were also collected on 225 consecutive ovarian cancer cases treated at the same medical center. Overall, 367/947 (38.7%) of mutation carriers had breast cancer (age at diagnosis 44.1 ± 10.4 years), 142 (15.0%) ovarian cancer (53.6 ± 10.1 years), and 438 (46.25%) were asymptomatic carriers (age at counseling 41.4 ± 11.2 years). Mean age at diagnosis of consecutive ovarian cancer cases was 53.6 ± 10.1 years. Of mutation carriers, 28/367 breast cancer cases (7.6%), 15/142 ovarian cancer cases (10.6%), and 11/438 asymptomatic carriers (2.5%) underwent prior appendectomy (P = 0.001 for breast/ovarian cancer when compared with asymptomatic carriers). In all but two cases, appendectomy was performed more than 10 years before cancer diagnosis or age at counseling. Of ovarian cancer patients, 12/225 (5.3%) underwent appendectomy, and in 10 appendectomy was performed 10 years or more before ovarian cancer diagnosis (P = 0.068 when compared with inherited ovarian cancer cases). This study suggests that prior appendectomy is more frequently noted in BRCA1 and BRCA2 carriers with breast and ovarian cancer than in unaffected mutation carriers. The mechanism for this association is elusive, and future analyses of ethnically diverse mutation carriers are needed to validate these results.
先前的研究表明,阑尾切除术可能会影响普通人群的癌症风险。目前尚无关于阑尾切除术对 BRCA1 和 BRCA2 携带者癌症风险影响的数据。从一家医疗中心接受咨询的 677 名 BRCA1(n=677)和 270 名 BRCA2(n=270)女性犹太以色列突变携带者中收集了阑尾切除术、癌症类型和诊断时年龄的数据。还收集了在同一医疗中心治疗的 225 例连续卵巢癌病例的数据。总体而言,947 名突变携带者中有 367 名(38.7%)患有乳腺癌(诊断时年龄 44.1±10.4 岁),142 名(15.0%)患有卵巢癌(53.6±10.1 岁),438 名(46.25%)为无症状携带者(咨询时年龄 41.4±11.2 岁)。连续卵巢癌病例的平均诊断年龄为 53.6±10.1 岁。在 367 名乳腺癌病例中,有 28 名(7.6%)、142 名卵巢癌病例中的 15 名(10.6%)和 438 名无症状携带者中的 11 名(2.5%)接受了先前的阑尾切除术(与无症状携带者相比,乳腺癌/卵巢癌的 P 值=0.001)。除了两例以外,阑尾切除术均在癌症诊断或咨询时年龄 10 年之前进行。在 225 名卵巢癌患者中,有 12 名(5.3%)接受了阑尾切除术,其中 10 名在卵巢癌诊断前 10 年或更久接受了阑尾切除术(与遗传性卵巢癌病例相比,P 值=0.068)。本研究表明,BRCA1 和 BRCA2 携带者中患有乳腺癌和卵巢癌的患者比未受影响的突变携带者更频繁地接受阑尾切除术。这种关联的机制尚不清楚,需要对不同种族的突变携带者进行进一步的分析来验证这些结果。